Telavancin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
  • HAP and VAP caused by susceptible isolates of S. aureus.
    • It should be reserved for use when alternative agents are not suitable.

NON-FDA APPROVED USES

  • S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: October 2, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Telavancin ID - 540538 A1 - Avdic,Edina,Pharm.D. AU - Pham,Paul,Pharm.D. BCPS Y1 - 2018/10/02/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -